Can basic and clinical research on placebo lead to evidence-based - - PowerPoint PPT Presentation

can basic and clinical research on placebo
SMART_READER_LITE
LIVE PREVIEW

Can basic and clinical research on placebo lead to evidence-based - - PowerPoint PPT Presentation

Can basic and clinical research on placebo lead to evidence-based clinical trials? Fabrizio Benedetti University of Turin Medical School, Turin, Italy Plateau Ros Labs, Plateau Ros, Switzerland Evidence from basic and clinical research


slide-1
SLIDE 1

Fabrizio Benedetti

University of Turin Medical School, Turin, Italy Plateau Rosà Labs, Plateau Rosà, Switzerland

Can basic and clinical research on placebo lead to evidence-based clinical trials?

slide-2
SLIDE 2

OVERVIEW

Patients’ expectations are crucial for the therapeutic outcome Repeated exposure to drugs may lead to substantial placebo responses Communication across participants may affect the therapeutic outcome Placebo responders and nonresponders can be identified a priori

Evidence from basic and clinical research

slide-3
SLIDE 3

Ritual of therapeutic act Psychosocial context

D2-D3 CB1 mu dopamine cannabinoids opioids Benedetti (2008) Annu Rev Pharmacol Toxicol Benedetti (2014) Neuron

anti-Parkinson cannabis narcotics

D r u g s

slide-4
SLIDE 4

Benedetti et al (1995) Lancet Colloca et al (2004) Lancet Neurol Benedetti et al (2016) Lancet Neurol

slide-5
SLIDE 5

No expectation

Benedetti et al (1995) Lancet Colloca et al (2004) Lancet Neurol Benedetti et al (2016) Lancet Neurol

slide-6
SLIDE 6

Pain reduction

BUPRENORPHINE TRAMADOL KETOROLAC METAMIZOL

  • pen
  • pen
  • pen
  • pen

hidden hidden hidden hidden

  • 1
  • 2
  • 3

Open injection Hidden injection

computer Pharmacodynamic effect Psychological effect

No expectation

Benedetti et al (1995) Lancet Colloca et al (2004) Lancet Neurol Benedetti et al (2016) Lancet Neurol

slide-7
SLIDE 7

TRIAL Met#2

(Colloca and Benedetti, Nature Rev Neurosci 6: 545-552, 2005)

Is metamizol (300 mg) effective in post-thymectomy pain? Open metamizol injection group (N=10) Hidden metamizol injection group (N=10)

Informed consent “You will receive metamizol but you don’t know when” Double blind

slide-8
SLIDE 8

Pain intensity (NRS) 1 2 3 4 5 6 2 4 6 8 10 Pain intensity (NRS) 2 4 6 8 10

Open (expected) injection of metamizol Hidden (unexpected) injection of metamizol

hours

No expectation

slide-9
SLIDE 9

R e m i f e n t a n i l

Positive expectation Negative expectation No expectation

Pain decrease

  • 1
  • 2
  • 3

GET TOLD

S a l i n e R e m i f e n t a n i l I n t e r r u p t i o n DLPFC ACC Hippocampus Bingel et al (2011) Science Trans Med

slide-10
SLIDE 10

OVERVIEW

Patients’ expectations are crucial for the therapeutic outcome Repeated exposure to drugs may lead to substantial placebo responses Communication across participants may affect the therapeutic outcome Placebo responders and nonresponders can be identified a priori

Evidence from basic and clinical research

slide-11
SLIDE 11

Inhibition Activation CB1 cannabinoid receptor  opioid receptor

Memory ON Memory ON Previous activation of  opioid receptors Previous activation of CB1 cannabinoid receptors

Benedetti et al. (2011) Nature Med

Activation likehood estimation (ALE) meta-analysis

slide-12
SLIDE 12

Lack of efficacy withdrawal Adverse event withdrawal Screen Randomise Active Control Assessment

McQuay et al (2008) Pain

Titrate to effect with active

Enriched Enrolment with Randomized Withdrawal

Increased placebo responses

slide-13
SLIDE 13

OVERVIEW

Patients’ expectations are crucial for the therapeutic outcome Repeated exposure to drugs may lead to substantial placebo responses Communication across participants may affect the therapeutic outcome Placebo responders and nonresponders can be identified a priori

Evidence from basic and clinical research

slide-14
SLIDE 14

1 day 2 days 3 days 4 days 5 days 6 days 7 days Benedetti et al (2014) Pain

slide-15
SLIDE 15

% increase

200 100

Socially infected

(negative expectations)

Not informed

(no expectations)

52% 86%

Benedetti et al (2014) Pain Benedetti (2014) Neuron Benedetti et al (2016) Lancet Neurol

% increase

200 100

slide-16
SLIDE 16

aspirin vs placebo aspirin vs placebo with a pre-existing nocebo effect

Socially infected

(negative expectations)

Not informed

(no expectations)

52% 86%

Benedetti et al (2014) Pain Benedetti (2014) Neuron Benedetti et al (2016) Lancet Neurol

slide-17
SLIDE 17

OVERVIEW

Patients’ expectations are crucial for the therapeutic outcome Repeated exposure to drugs may lead to substantial placebo responses Communication across participants may affect the therapeutic outcome Placebo responders and nonresponders can be identified a priori

Evidence from basic and clinical research

slide-18
SLIDE 18

Placebo non-responder Placebo responder

Genetics

slide-19
SLIDE 19

Personality

Placebo non-responder Placebo responder

Suggestibility Hypnotic susceptibility

De Pascalis et al 2002 Derbyshire and Oakley 2013 Huber et al 2013

Optimism Pessimism

Geers et al 2005, 2007, 2010

Dopamine-related personality traits (sensitivity to incentives and rewards)

Schweinhardt et al 2009

Ego-resiliency Altruism Angry hostility

Pecina et al 2013

slide-20
SLIDE 20

Learning…

…can create placebo responders and non responders in the lab

Matching or mismatching what patients expect and what they get

Placebo responder Placebo non-responder

PLA Exp ANA Get ANA Exp ANA Get ANA PLA Exp ANA Get No ef Exp ANA Get No ef PLA Colloca & Benedetti (2006) Pain Benedetti & Frisaldi (2014) Pain Manag

slide-21
SLIDE 21

CONCLUSIONS

Patients’ expectations should be assessed in all clinical trials Drug history should be assessed carefully to ascertain possible learning effects Communication across participants should be avoided Future research should be aimed at better identifying placebo (non)responders

Evidence from basic and clinical research

slide-22
SLIDE 22

NEUROPHYSIOLOGY

Elisa Frisaldi Jennifer Durando Sergio Vighetti Antonella Pollo Luana Colloca

PSYCHOLOGY

Elisa Carlino Alessandro Piedimonte Martina Amanzio Claudia Arduino Rosalba Rosato Sara Palermo Diletta Barbiani Eleonora Camerone

NEUROLOGY

Leonardo Lopiano Maurizio Zibetti Mario Rizzone Innocenzo Rainero Giovanni Asteggiano

THORACIC SURGERY

Giuliano Maggi Caterina Casadio

NEUROSURGERY

Michele Lanotte

ENDOCRINOLOGY

Catherine Blanchard Wilma Thoen Sara Dogue

NEUROIMAGING

Carlo Porro Fausta Lui Franco Cauda

University of Turin Medical School, Italy Plateau Rosa Laboratories, Switzerland

Thanks to: